The introduction of statins in approximately 1987 marked a significant turning point in the field of cardiovascular medicine. By effectively lowering levels of harmful low-density lipoprotein (LDL) cholesterol, these pharmaceutical agents revolutionised the prevention and long-term management of heart disease. Their development served as a vital bridge between foundational scientific research into cholesterol metabolism and the creation of practical, life-saving treatments that have since become a cornerstone of modern clinical practice.

The widespread adoption of statins has fundamentally altered the approach to mitigating the risk of serious health complications. By inhibiting the enzyme responsible for cholesterol production in the liver, these medications have proven highly effective in stabilising arterial plaques and reducing the likelihood of life-threatening events. Their impact on public health is profound, as they have become one of the most frequently prescribed classes of drugs for patients at risk of developing cardiovascular conditions.

The clinical success of this therapy is defined by several key contributions to patient care:

• Significant reduction of LDL cholesterol levels in the bloodstream.
• Decreased incidence of primary and secondary heart attacks.
• Lowered risk of stroke among high-risk populations.
• Improved long-term outcomes for patients with established cardiovascular disease.
• Establishment of a standardised pharmacological approach to lipid management.

The journey from laboratory discovery to widespread therapeutic use represents a major achievement in pharmaceutical science. By addressing the underlying biological mechanisms of cholesterol regulation, statins have provided clinicians with a reliable tool to manage one of the leading causes of mortality globally. This transition from basic research to routine medical intervention continues to underpin the strategy for reducing the burden of cardiovascular disease in patients across the world.